Moodle
You are not logged in. (Login)
Skip Check this out...
Show or hide block

Check this out...

Welcome to E-Menai

ambien alcohol wellbutrin "The approval is the culmination of over three years of effort from our partners at Applied Pharma Research and the internal team at Kowa," said William Maichle, Chief Operating Officer of Kowa Pharmaceuticals America, Inc. We believe Cambia addresses these needs and will be a valuable addition to physicians' migraine armamentarium. KPA and APR have been granted patents that cover Cambia through 2026.kowapharma.apr. and King Pharmaceuticals, Inc. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act.

.


NewsA Level

S. According to a recent peer reviewed publication authored by leading migraine researchers, more than 70 percent of patients indicated that they were less than completely satisfied with their current treatment. Acura Pharmaceuticals, Inc. King's wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacturing and marketing of pharmaceutical products for food producing animals..